Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
cdepharma.co

See what CB Insights has to offer

Stage

Acquired | Acquired

About Comprehensive Drug Enterprises

Comprehensive Drug Enterprises, founded in 2005, is a specialty pharmaceutical company that focuses on the development of transmucosal drug delivery, with special emphasis on sublingual and nasal administration pharmaceuticals.

Comprehensive Drug Enterprises Headquarter Location

Sha Tin,

Hong Kong

852-2607-4100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Comprehensive Drug Enterprises

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Comprehensive Drug Enterprises is included in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Comprehensive Drug Enterprises Patents

Comprehensive Drug Enterprises has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/27/2013

Diseases of the eye and adnexa, Ophthalmology, Food additives, Disorders of sclera and cornea, Disorders of conjunctiva

Application

Application Date

3/27/2013

Grant Date

Title

Related Topics

Diseases of the eye and adnexa, Ophthalmology, Food additives, Disorders of sclera and cornea, Disorders of conjunctiva

Status

Application

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.